Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarker Identification for Immulina Ingestion
NCT05556967Phase 3Completed
- Sponsor
- University of Mississippi Medical Center
- Start
- Aug 2023
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial, sponsored by University of Mississippi Medical Center. Primary endpoints: gamma-linolenic acid at 7 hours, Sulfoquinovose at 7 hours and 6 more. Started Aug 2023; status: completed.
Beyond the preview
Go deeper on NCT05556967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05556967.